Nuwellis Inc vs Novavax Inc — how do they compare? Nuwellis Inc trades at $1.49 (market cap $542.80K), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Novavax Inc is far larger — about 2413.4× Nuwellis Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | NVAX | |
|---|---|---|
Market Cap | $542.80K | $1.31B |
Sector | Technology | Health |
52-Week High | $220.50 | $11.19 |
52-Week Low | $1.42 | $6.22 |
Enterprise Value | -$1.27M | $889.30M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Trailing returns across standard periods
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →